FLT3 and acute myeloid leukemia: The QuANTUM-R study of quizartinib versus salvage chemotherapy in adults aged ≥ 18 years with relapsed/refractory AML with a FLT3 internal tandem duplication showed a relative Q-TWiST gain of 20.3% [28].